

DOT Downtime Orders Report


Access Steps & Sample Report

How to Access the DOWNTIME DOT REPORT – in Cerner® and in 724DTV

In PowerChart

The report appears in the Documentation component. The diagram below displays how the document appears in PowerChart®. The Downtime DOT Orders Report is available in PowerChart® documents in the Downtime Documentation category. The diagram below displays how the document appears in PowerChart®.

Note: If you do not see the Downtime DOT Report in the Documentation component check your filters; expand filters as needed to see the report.



In 724DTV

The most recent report will be available in the Non-expiring Documents section of the patient chart. The diagram below demonstrates how the document will appear in the 724DTV.

CSTDOWNTIME, PATIENT A Age: 30 years Female Status: Preadmit Location: BCC VA MDC
 MRN: 740019403 P TID: FIN: 7400000044113, 7400000044133 Weight Admit: -- Weight Dosing: --
 DOB: 06/17/1990 Height: --
 Allergies: ** Unknown **

Precautions: --

Patient Information Documents Last Updated: 06/16/21 14:51

Current Documents Non-Expiring Documents
 Start Date: 06/16/2021 14:51 1 Month

Documents Filter: Downtime Documentation Print Document

06-16-2021 14:51 SYSTEM, SYSTEM Center - "Downtime DOT Orders Report"

Result Type	Downtime DOT Orders Report
Result Date	06-16-2021 14:51
Result Status	Auth (Verified)
Result Title	Downtime DOT Orders Report
Performed By	SYSTEM, SYSTEM Center on 06/16/21 14:51 PDT
Created By	SYSTEM, SYSTEM Center on 06/16/21 14:51 PDT
Encounter Info	7400000044113, BCC VA Van Ctr, 06/16/21 14:48 PDT

*** Final Report ***

Downtime DOT Orders Report

Report Content Created: 16-JUN-2021 14:51
 Report Includes Orders From: 15-JUN-2021 to 21-JUN-2021
 CST Center Document Type Alias: * 9429 *

Important notes about the design of this report:

- In certain scenarios, identical duplicate reports are created on the patient. The duplicate will be removed within 1 hour or with next order action, whichever comes first.
- When orders requiring cosignature are signed, the report is not immediately updated to immediately reflect the cosignature has been completed and remove the cosign flag. Report is updated in 1 hour or with next order action, whichever comes first.
- Documentation Types must be Dynamic Documents to be part of the DOT report lifecycle.

Jira Ticket #	CST-96425
How-to questions?	http://cstcernerhelp.healthcarebc.ca/
Need further support?	CST Phone Support: 1-844-214-7444

DOIDT, TESTTWO MRN: 740019413Room/Bed BCC VA IVWR.FN: 740000044203

Result Type	Downtime DOT Orders Report
Result Date	06-17-2021 17:38
Result Status	Auth (Verified)
Result Title	Downtime DOT Orders Report
Performed By	SYSTEM, SYSTEM Cerner on 06/17/21 17:38 PDT
Verified By	SYSTEM, SYSTEM Cerner on 06/17/21 17:38 PDT
Encounter Info	740000044203, BCC VA Van Ctr, 06/17/21 16:55 PDT

*** Final Report ***

Downtime DOT Orders Report

Report Content Created: 17-JUN-2021 17:38
 Report Includes Orders From: 16-JUN-2021 to 22-JUN-2021
 CST Cerner Document Type Alias: * 9429 *

Do not write on this report.

Scan/Index to Downtime DOT Orders Report in CST Cerner after Downtime.

DOB: 16-JUN-1995 Age: 26 Years PHN: 9874061729 Dual Modality: No

PowerPlan Orders

**ONC LY LYCHOPR DOXOrubicin Option
 ONCP LY LYCHOPR Pretreatment Plan**

Baseline Labs (Day 1)

Order Sentence	Day 1 18-JUN-2021 08:00
CBC and Differential, Blood, Routine, Collection: 18-Jun-2021, once, Order for future visit	Future 18-JUN-2021 08:00
Bilirubin Total, Blood, Routine, Collection: 18-Jun-2021, once, Order for future visit Order Comment:SPECIAL COLLECTION REQUIREMENTS: Please refer to specific site Laboratory Test Manual.	Future 18-JUN-2021 08:00
Alanine Aminotransferase, Blood, Routine, Collection: 18-Jun-2021, once, Order for future visit	Future 18-JUN-2021 08:00
Hepatitis B Core Antibody Total BCCDC, Blood, Routine, Collection: 18-Jun-2021, once, Order for future visit	Future 18-JUN-2021 08:00
Hepatitis B Surface Antigen BCCDC, Blood, Routine, Collection: 18-Jun-2021, once, Order for future visit	Future 18-JUN-2021 08:00
Hepatitis B Surface Antibody BCCDC, Blood, Routine, Collection: 18-Jun-2021, once, Order for future visit	Future 18-JUN-2021 08:00
Note: If HBsAg or HBcoreAb positive, start lamivudine 100 mg PO daily for the duration of chemotherapy and continue for one year from treatment completion for patients who are HBsAg positive and for six months for patients who are HBcoreAb positive	

**ONC LY LYCHOPR DOXOrubicin Option
 ONCP LY LYCHOPR DOXOrubicin Option - Cycle 1**

Chemotherapy (Day 1)

		Day 1		
--	--	-------	--	--

Order Sentence	Day 1 18-JUN- 2021 08:00	18-JUN- 2021 08:30	Day 1 18-JUN- 2021 08:50	Day 1 18-JUN- 2021 09:05
Note: Link to Protocol: Treatment of Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRIStine, predniSONE and rITUXimab (CHOP-R)				
Note: Revised: 30 Jun 2020				
Note: Pre-Chemo Metrics				
Note: Neutrophils Greater Than or Equal to $0.8 \times 10^9/L$ within 96 hours				
Note: Pre-Medications				
Note: Patient to take own supply of pre-medications. RN/Pharmacist to confirm				
dexamethasone, 8 mg, PO, once oncology, drug form: tab, first dose: Routine, start: 18-Jun-2021, Use Patient Supply Order Comment:Between 30 and 60 minutes prior to treatment. Day 1 MAR Note:Take with food.	Future (-30 Minutes) 18-JUN-2021 08:00			
ondansetron, 8 mg, PO, once oncology, drug form: tab, first dose: Routine, start: 18-Jun-2021, Use Patient Supply Order Comment:Do not give if patient given netupitant-palonosetron. Between 30 and 60 minutes prior to treatment. Day 1	Future (-30 Minutes) 18-JUN-2021 08:00			
aprepitant, 125 mg, PO, once oncology, drug form: cap, first dose: Routine, start: 18-Jun-2021, Use Patient Supply Order Comment:Between 30 and 60 minutes prior to treatment. Day 1	Future (-30 Minutes) 18-JUN-2021 08:00			
Note: Reminder to deselect ondansetron if giving netupitant-palonosetron				
Note: Treatment Regimen				
Zero Time, once oncology, 18-Jun-2021, Future Order, Day 1, -1		Future 18-JUN- 2021 08:30		
Note: BC Cancer and CONs - select syringe for peripheral and central administration				
Note: SPH and VGH - select syringe for peripheral administration OR bag for central administration				
DOXOrubicin - oncology, 100 mg, IV, once oncology, drug form: syringe-inj, first dose: Routine, start: 18-Jun-2021 Order Comment:Day 1 Target Dose: DOXOrubicin - oncology 50 mg/m ² 17-Jun-2021 17:07:07		Future 18-JUN- 2021 08:30		
Note: If using a peripheral line, infuse vinca alkaloid via gravity only; DO NOT USE an infusion pump				
vinCRIStine - oncology, 2.8 mg, IV, once oncology, administer over: 15 minute, drug form: bag, first dose: Routine, start: 18-Jun-2021 Order Comment:Day 1 Target Dose: vinCRIStine - oncology 1.4 mg/m ² 17-Jun-2021 17:07:48			Future (+20 Minutes) 18-JUN-2021 08:50	
cyclophosphamide - oncology, 1,500 mg, IV, once oncology, administer over: 20 minute, drug form: bag, first dose: Routine, start: 18-Jun-2021 Order Comment:Day 1 Target Dose: cyclophosphamide - oncology 750 mg/m ² 17-Jun-2021 17:07:54				Future (+35 Minutes) 18-JUN-2021 09:05
Note: See Prescriptions OR Prescriptions (Inpatient Use Only) Phase for predniSONE				
Note: See rITUXimab phase for rITUXimab and associated orders				
Note: Additional Orders				
Note: Any additional orders will be displayed below. Please review and adjust scheduled administration time as needed				

Prescriptions

Order Sentence	Start Dt/Tm	End Dt/Tm
predniSONE, 100 mg, PO, as directed, drug form: tab, dispense qty: 21 day, start: 18-JUN-2021 08:00 Order Comment:Round dose to nearest 25 mg. Prescription is part of a combined IV/PO protocol. Dispense quantity = 1 cycle Target Dose: predniSONE 45 mg/m ² 17-Jun-2021 17:08:17	Future 18-JUN-2021 08:00	

Scheduling

--	--	--

Order Sentence	Start Dt/Tm	End Dt/Tm
Infusion Chemotherapy Visit, 18-JUN-2021 08:00, Day 1, ONCP LY LYCHOPR DOXOrubicin Option - Cycle 1, Within 2 Weeks, Cycle 1: Chair time 180 minutes; Nurse time 110 minutes, Chair Time: 150 minutes, Nurse Time: 80 minutes, ONCP LY LYCHOPR DOXOrubicin Option, No Order Comment:Day 1	Future 18-JUN-2021 08:00	
Infusion riTUXimab Chemotherapy Visit, 19-JUN-2021 08:00, Treatment 2, ONCP LY LYCHOPR DOXOrubicin Option - Cycle 1, Within 2 Weeks, Day 1: INITIAL - Chair: 290 min, Nurse: 0 min. SUBSEQUENT - Chair: 105 min, Nurse: 0 min. SC - Chair: 25 min, Nurse: 0 min. Day 2 (Cycle 1): INITIAL - Chair 330 min, Nurse 55 min. Day 2 (Cycle 2+): INITIAL - Chair 325 min, Nurse 50 min, Chair Time: 5 minutes, Nurse Time: 5 minutes, ONCP LY LYCHOPR DOXOrubicin Option - riTUXimab, No Order Comment:Treatment 2	Future 19-JUN-2021 08:00	
Follow Up - Clinic - Oncology On Treatment, 18-JUN-2021 08:00, Follow Up: 3 weeks, Physician Specialty: Medical Oncology, Tumor Group: Lymphoma and Myeloma, BCC VA Chemo	Future 18-JUN-2021 08:00	18-JUN-2021 08:00
Note: Go to treatment calendar to send next cycle to scheduling wait list		

riTUXimab (Treatment 2)

Order Sentence	Treatment 2 19-JUN-2021 08:00	Treatment 2 19-JUN-2021 08:30
Note: Pre-Medications		
diphenhydramINE, 50 mg, PO, once oncology, drug form: cap, first dose: Routine, start: 19-Jun-2021, Use Patient Supply Order Comment:Between 30 and 60 minutes prior to riTUXimab	Future (-30 Minutes) 19-JUN-2021 08:00	
acetaminophen, 650 mg, PO, once oncology, drug form: tab, first dose: Routine, start: 19-Jun-2021, Use Patient Supply Order Comment:Between 30 and 60 minutes prior to riTUXimab	Future (-30 Minutes) 19-JUN-2021 08:00	
Note: If hypersensitivity reactions have occurred, see protocol or BC Cancer hypersensitivity guidelines (SCDRUGRX) for additional pre-medications		
Note: Hypersensitivity Management		
Note: Have Hypersensitivity Reaction Medications and Protocol Available. Contact provider for additional orders		
diphenhydramINE, 50 mg, IV, once oncology, PRN other (see comment), drug form: inj, first dose: Routine, start: 19-Jun-2021, stop: 19-Jun-2021 Order Comment:For hypersensitivity reaction	Future 19-JUN-2021 08:00	
hydrocortisone, 100 mg, IV, once oncology, PRN other (see comment), drug form: inj, first dose: Routine, start: 19-Jun-2021, stop: 19-Jun-2021 Order Comment:For hypersensitivity reaction	Future 19-JUN-2021 08:00	
epinephrine 1 mg/mL inj, 0.5 mg 0.5 mL, IM, q5min, PRN anaphylaxis, order duration: 3 doses or times, drug form: inj, first dose: Routine, start: 19-Jun-2021, stop: 19-Jun-2021	Future 19-JUN-2021 08:00	
salbutamol, 5 mg, nebulized, q20min, PRN shortness of breath or wheezing, order duration: 3 doses or times, drug form: neb, first dose: Routine, start: 19-Jun-2021, stop: 19-Jun-2021	Future 19-JUN-2021 08:00	
Note: Treatment Regimen		
Zero Time, once oncology, 19-Jun-2021, Future Order, Treatment 2, -1		Future 19-JUN-2021 08:30
Note: For SPH and VGH refer to PDTM for riTUXimab monitoring requirements		
Note: Initial Infusion: riTUXimab na?ve or as clinically indicated due to prior intolerance		
riTUXimab - oncology, 750 mg, IV, once oncology, drug form: bag, first dose: Routine, start: 19-Jun-2021 Order Comment:Initial Infusion: Start infusion at 50 mg/hour, after 1 hour, increase by 50 mg/hour every 30 minutes to maximum 400 mg/hour unless toxicity occurs. Refer to Protocol/PDTM for monitoring requirements. If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discomfort or exacerbation of any existing symptoms occur, stop infusion and page		Future 19-JUN-2021 08:30

physician Target Dose: ritUXimab - oncology 375 mg/m2 17-Jun-2021 17:08:04		
Note: Subsequent Infusion: Patient did not tolerate a full dose of IV ritUXimab (experienced severe reactions requiring early termination) in the previous treatment		
Note: Subcutaneous Injection: Patient tolerated a full dose of IV ritUXimab (no severe reactions requiring early termination)		
Note: During treatment with subcutaneous ritUXimab, administer other subcutaneous drugs at alternative injection sites whenever possible.		
Note: ritUXimab IV or SC may be given before or after chemotherapy, but within 72 hours after day 1 of CHOP		
Note: Supportive Care Medications		
diphenhydRAMINE, 50 mg, PO, q4h oncology, PRN other (see comment), drug form: cap, first dose: Routine, start: 19-Jun-2021, stop: 19-Jun-2021	Future 19-JUN-2021 08:00	
Order Comment:For ritUXimab reaction prophylaxis. If ritUXimab IV infusion exceeds 4 hours		
acetaminophen PRN range dose, dose range: 650 to 975 mg, PO, q4h oncology, PRN other (see comment), drug form: tab, first dose: Routine, start: 19-Jun-2021, stop: 19-Jun-2021	Future 19-JUN-2021 08:00	
Order Comment:For ritUXimab reaction prophylaxis. If ritUXimab IV infusion exceeds 4 hours		

Prescriptions (Inpatient Use Only)

Order Sentence	Start Dt/Tm	End Dt/Tm
predniSONE, 100 mg, PO, qdaily with breakfast, order duration: 5 doses or times, drug form: tab Order Comment:Round dose to nearest 25 mg. Medication is part of a combined IV/PO protocol. Days 1 to 5 Target Dose: predniSONE 45 mg/m2 17-Jun-2021 17:09:54	Planned 18-JUN-2021 08:00	

*** Document History ***

* Perform by SYSTEM, SYSTEM Center on 06/17/21 17:38 PDT
 * VERIFY by SYSTEM, SYSTEM Center on 06/17/21 17:38 PDT